cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Passage Bio Inc
2 own
7 watching
Current Price
$1.55
$-0.01
(-0.64%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
84.55M
52-Week High
52-Week High
5
52-Week Low
52-Week Low
1.04
Average Volume
Average Volume
0.1M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization84.55M
icon52-Week High5
icon52-Week Low1.04
iconAverage Volume0.1M
iconDividend Yield--
iconP/E Ratio--
What does the Passage Bio Inc do?
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Read More
How much money does Passage Bio Inc make?
News & Events about Passage Bio Inc.
Globe Newswire
3 months ago
PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the appointment of William Chou, M.D. as chief executive officer (...
Globe Newswire
6 months ago
PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Simona King, chief financial officer of Passage Bio, will ...
Ticker Report
8 months ago
Zacks Investment Research cut shares of Passage Bio (NASDAQ:PASG Get Rating) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning, Zacks.com reports. According to Zacks, Passage Bio Inc. is a genetic medicines company. It is focused on ...
Globe Newswire
9 months ago
PHILADELPHIA, May 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that additional clinical and biomarker data from Cohort 1 in the ...
Frequently Asked Questions
Frequently Asked Questions
What is Passage Bio Inc share price today?
plus_minus_icon
Can Indians buy Passage Bio Inc shares?
plus_minus_icon
How can I buy Passage Bio Inc shares from India?
plus_minus_icon
Can Fractional shares of Passage Bio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Passage Bio Inc stocks?
plus_minus_icon
What is today’s traded volume of Passage Bio Inc?
plus_minus_icon
What is today’s market capitalisation of Passage Bio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Passage Bio Inc?
plus_minus_icon
What percentage is Passage Bio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Passage Bio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.55
$-0.01
(-0.64%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
IMMUNIC INC
IMMUNIC INC
$2.87
$0.30 (11.67 %)
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$1.75
$-0.17 (-8.85 %)
Seelos Therapeutics Inc
Seelos Therapeutics Inc
$0.84
$-0.03 (-2.96 %)
Greenwich LifeSciences Inc
Greenwich LifeSciences Inc
$20.43
$-0.37 (-1.79 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
IMMUNIC INC
IMMUNIC INC
$2.87
$0.30 (11.67 %)
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$1.75
$-0.17 (-8.85 %)
Seelos Therapeutics Inc
Seelos Therapeutics Inc
$0.84
$-0.03 (-2.96 %)
Greenwich LifeSciences Inc
Greenwich LifeSciences Inc
$20.43
$-0.37 (-1.79 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00